4 results
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
To assess the efficacy of GV-971 compared with placebo on cognition and global function in participants with mild to moderate Alzheimer's disease (AD).
Primary objectivesTo study whether Geranyl-Geranyl Acetone (GGA) reduces left ventricular (LV) diastolic dysfunction in patients with HFpEF compared to placebo (and to assess/confirm its effectiveness and safety in patients with HFpEF)Secondary…
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…